A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
Clinical trial NCT01984242 · COMPLETED
Trial details
- NCT number
- NCT01984242
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-08
- Primary completion
- 2016-10-17
- Enrollment
- 305
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.